


54
55

4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-cyclopropylmethyl-benzamide (E130)	4-Iodo-N-cyclopropylmethyl-benzamide (D23)	391
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-phenyl]-1-pyrrolidin-1-yl-methanone (E131)	1-(4-Iodo-phenyl)-1-pyrrolidin-1-yl-methanone (D24)	391
N-Cyclobutyl-4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-benzamide (E132)	4-Iodo-N-cyclobutyl-benzamide (D25)	391
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N,N-diethyl-benzamide (E133)	4-Iodo-N,N-diethyl-benzamide (D26)	393
N-(2-Cyano-ethyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-benzamide (E134)	4-Iodo-N-(2-cyano-ethyl)-N-methyl-benzamide (D27)	404
1-[3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-phenyl]-1-morpholin-4-yl-methanone (E135)	1-(3-Iodo-phenyl)-1-morpholin-4-yl-methanone (D28)	407
3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-cyclopropylmethyl-benzamide (E136)	3-Iodo-N-cyclopropylmethyl-benzamide (D29)	391
3-Cyclobutyl-7-[4-(morpholine-4-sulfonyl)-phenoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E137)	4-(4-Iodo-benzenesulfonyl)-morpholine (D30)	443
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N,N-diethyl-benzenesulfonamide (E138)	4-Iodo-N,N-diethyl-benzenesulfonamide (D31)	429

Example 139

7-Benzoyloxy-3-cyclohexyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E139)




- 5 Example 139 (E139) was prepared from Description 2 (D2) and cyclohexanone using the method described for Example 1; MS (ES+) m/e 336 [M+H]⁺.

Example 140

3-Cyclobutyl-7-[[2-(1-piperidinyl)-5-pyrimidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E140)

10



Sodium hydride (60% disp. in mineral oil, 44 mg, 1.1 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) (200 mg, 0.92 mmol) and

85
56

copper (I) bromide (184 mg, 1.3 mmol) in pyridine (10 ml) at 0 °C. After stirring for 0.5 hour at room temperature, 5-bromo-2-(1-piperidiny)pyrimidine (D32) (0.669 g, 2.8 mmol) was added and the reaction mixture heated at reflux for 2 hours. The reaction was allowed to cool, filtered and the filtrate was concentrated *in vacuo*. The crude residue was dissolved with ethyl acetate and washed with water and brine. The organic layer was dried (magnesium sulfate), filtered and concentrated *in vacuo*. Purification of the resulting residue by column chromatography eluting with a mixture of .880 ammonia: ethanol: dichloromethane (0.25: 2.25: 97.5 to 1: 9: 90) afforded the title compound (E140). MS (ES+) *m/e* 379 [M+H]⁺.


Examples 141-143

Examples 141-143 (E141-E143) were prepared from 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) and the appropriate bromides indicated in the table using an analogous method to that described for Example 140 (E140):

Example	Bromide	LC/MS (M+H ⁺)
3-Cyclobutyl-7-([2-(1-pyrrolidiny)-5-pyrimidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E141)	5-Bromo-2-(1-pyrrolidiny)pyrimidine (D33)	385
3-Cyclobutyl-7-([2-(1,1-dioxido-4-thiomorpholiny)-5-pyrimidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E142)	4-(5-Bromo-2-pyrimidinyl)thiomorpholine 1,1-dioxide (D34)	429
5-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-2-pyrimidinamine (E143)	5-Bromo-N-methyl-2-pyrimidinamine (D35)	325

Example 144

3-Cyclobutyl-7-([2-(methyloxy)-5-pyrimidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E144)



Example 144 (E144) was prepared from 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) and 5-bromo-2-(methyloxy)pyrimidine (PCT Int. Appl. PCT (2002), WO 02/62423) using the method described for Example 140 (E140); MS (ES+) *m/e* 326 [M+H]⁺.

Examples 145-147

56
57

Examples 145-147 (E145-E147) were prepared from 3-cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E6) and the appropriate acid indicated in the table using an analogous method to that described for Example 13 (E13):

Example	Acid	LC/MS (M+H ⁺)
1-[4-({4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl}carbonyl)phenyl]-2-pyrrolidinone (E145)	4-(2-Oxo-1-pyrrolidinyl)benzoic acid	488
3-Cyclobutyl-7-[(1-[[3-(methylsulfonyl)phenyl]carbonyl]-4-piperidinyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E146)	3-(Methylsulfonyl)benzoic acid	483
3-Cyclobutyl-7-[(1-[(1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-6-yl)carbonyl]-4-piperidinyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E147)	3,4-Dihydro-2H-1-benzothiopyran-6-carboxylic acid 1,1-dioxide	509

Examples 148-150

Examples 148-150 (E148-E150) were prepared from 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) and the appropriate alcohol indicated in the table the method used for the preparation of Example 5a (E5a) followed by the method described for the preparation of Example 5 (E5).

Example	Alcohol	LC/MS (M+H ⁺)
3-Cyclobutyl-7-[(3S)-3-pyrrolidinylmethyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E148)	1,1-Dimethylethyl (3S)-3-(hydroxymethyl)-1-pyrrolidinecarboxylate	301
3-Cyclobutyl-7-[(3S)-3-piperidinylmethyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E149)	1,1-Dimethylethyl (3S)-3-(hydroxymethyl)-1-piperidinecarboxylate	315
3-Cyclobutyl-7-[(3S)-3-piperidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E150)	1,1-Dimethylethyl (3S)-3-hydroxy-1-piperidinecarboxylate	301

Examples 151-153

Examples 151-153 (E151-E153) were prepared from the appropriate amine indicated in the table and morpholine carbamoyl chloride using the method described for Example 52:

Example	Amine	LC/MS (M+H ⁺)
---------	-------	------------------------------

87
58

3-Cyclobutyl-7-([[(3S)-1-(4-morpholinylcarbonyl)-3-piperidinyl]methyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E151)	3-Cyclobutyl-7-([[(3S)-3-piperidinylmethyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E149)	428
3-Cyclobutyl-7-([[(3S)-1-(4-morpholinylcarbonyl)-3-pyrrolidinyl]methyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E152)	3-Cyclobutyl-7-([[(3S)-3-pyrrolidinylmethyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E148)	414
3-Cyclobutyl-7-([[(3S)-1-(4-morpholinylcarbonyl)-3-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E153)	3-Cyclobutyl-7-([[(3S)-3-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E150)	414

Examples 154-156

5 Examples 154-156 (E154-E156) were prepared from the appropriate amine indicated in the table and 4-cyanobenzoyl chloride using an analogous method to that described for Example 43 (E43):

Example	Amine	LC/MS (M+H ⁺)
4-([[(3S)-3-([[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy)methyl]-1-piperidinyl)carbonyl]benzonitrile (E154)	3-Cyclobutyl-7-([[(3S)-3-piperidinylmethyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E149)	444
4-([[(3S)-3-([[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy)methyl]-1-pyrrolidinyl)carbonyl]benzonitrile (E155)	3-Cyclobutyl-7-([[(3S)-3-pyrrolidinylmethyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E148)	430
4-([[(3S)-3-([[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy)-1-piperidinyl]carbonyl]benzonitrile (E156)	3-Cyclobutyl-7-([[(3S)-3-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E150)	430

Examples 157-159

10 Examples 157-159 (E157-E159) were prepared from the appropriate amine indicated in the table and tetrahydro-pyran-4-carboxylic acid using an analogous method to that described for Example 13 (E13):

Example	Amine	LC/MS (M+H ⁺)
3-Cyclobutyl-7-([[(3S)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-3-pyrrolidinyl]methyl]	3-Cyclobutyl-7-([[(3S)-3-pyrrolidinylmethyl]oxy]-2,3,4,5-	413